



FOR IMMEDIATE RELEASE

August 6, 2019

Contact: Jacqueline Clark, jacqueline@sqcomms.com

Charlie Patterson, charlie@sqcomms.com

**DEA Registrant Biopharmaceutical Research Company adds
Celebrated Surgeon Charles Schumacher and Compliance Expert Louis Milione to Board
of Advisors**

MONTEREY, CA - Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) registrant, is pleased to announce the addition of Charles S. Schumacher, M.D, an orthopaedic surgeon at Covington Orthopedic Sports Medicine Institute, and Louis J. Milione, Senior Managing Director with Guidepost Solutions' Monitoring, Compliance and Investigations practice to its Board of Advisors.

"Dr. Schumacher and Mr. Milione are tremendous assets to the BRC Board of Advisors," said George Hodgkin, founder and CEO of BRC. "These gentlemen will offer invaluable insight into how our company can best navigate DEA regulations and optimize our clinical research. We look forward to rolling up our sleeves to build a framework that ensures BRC's position as a leader in federally compliant cannabis research and cultivation."

As members of the Board of Advisors, Dr. Schumacher and Mr. Milione will provide BRC with regulatory guidance, strategic advice related to their areas of expertise, and insight into industry trends. The Board also assists in the recruitment of new talent, and serves as a sounding board for business strategy and planning.

"The emergence of cannabis as medicine is rapidly evolving, but more research is needed to fully understand its medicinal value and limits," said Dr. Schumacher, a Harvard and Stanford University trained orthopaedic surgeon now specializing in hip and knee surgery. "I'm eager to work with BRC as their researchers strive to better understand the cannabis plant and its therapeutic potential for patients struggling with chronic pain, inflammatory conditions, and other ailments." Dr. Schumacher added that "Additional research is also needed to evaluate the risk and potential harm of routine use of cannabis in the medical field."

With more than 20 years experience at the DEA, Louis Milione will provide critical guidance as BRC seeks final DEA approval to grow cannabis for research purposes. Mr. Milione is a globally

recognized Controlled Substances Act (CSA) expert and former Assistant Administrator of DEA's Diversion Control Division. As Assistant Administrator, he supervised and led DEA's domestic and international programs to prevent, detect and investigate the diversion of controlled substances. He spearheaded the regulation of more than 1.6 million DEA registrants across the entire pharmaceutical value chain. In his decorated career at DEA, he also led several of the DOJ's most sensitive and significant criminal investigations. He is a recipient of the Service to America Justice and Law Enforcement Medal (SAMMIE).

“As BRC and other research companies seek access and permission to grow cannabis for research purposes, adhering to the letter of the law is paramount,” Milione stated. “BRC has already demonstrated a strong commitment to complying with DEA regulations, and I look forward to working with BRC as they seek authorization to grow their own cannabis samples.”

About Biopharmaceutical Research Company

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world. BRC also conducts federally compliant cannabis-specific analytical activities.

George Hodgin is a graduate of the Stanford Graduate School of Business, a former Navy SEAL and the CEO of Biopharmaceutical Research Company near Monterey, CA. To learn more about BRC's work, visit <https://www.biopharmaresearchco.com/>.

###